Benjamin D Powers1, Luke D Rothermel2, Jason B Fleming2, Jonathan R Strosberg2, Daniel A Anaya2. 1. Department of Gastrointestinal Oncology, Moffitt Cancer Center, 12902 Magnolia Dr., Tampa, FL, 33612, USA. Benjamin.Powers@moffitt.org. 2. Department of Gastrointestinal Oncology, Moffitt Cancer Center, 12902 Magnolia Dr., Tampa, FL, 33612, USA.
Abstract
BACKGROUND: Surgical resection for asymptomatic, localized, well-differentiated pancreatic neuroendocrine tumors (PNETs) is common yet controversial. Studies using overall survival as an endpoint have shown a benefit for resection; however, these results may be due to treatment selection bias. We assessed the impact of surgery on both overall (OS) and cancer-specific survival (CSS) for asymptomatic patients with stage I PNETs (AJCC 8th edition). METHODS: Using SEER data, we identified 709 patients from 2007 to 2015 with well- and moderately differentiated stage I PNETs. We performed Kaplan-Meier survival estimates and adjusted Cox regression for OS and CSS. RESULTS: Among 709 patients, 628 (88.6%) underwent surgery. There were 37 overall deaths and 11 cancer-specific deaths. All cancer-specific deaths occurred within 3 years of diagnosis. Five-year OS and CSS rates were 89% and 98%, respectively, for the population. Five-year OS rates were 56% in the non-surgical cohort versus 92% in the surgical cohort (log rank, p < 0.001). However, the 5-year CSS rates were similar; 94% in the non-surgical group and 98% in the surgical group (log rank, p = 0.207). On multivariable analysis, surgery predicted improved OS but not CSS. CONCLUSION: Although OS is superior in surgically treated stage I PNETs, CSS is not improved, implying treatment selection bias towards surgery being performed in healthier patients. These data suggest that overall survival is a problematic endpoint for the study of asymptomatic, stage I PNETs. Surgery should be individualized for this cohort of patients as the primary cause of death is non-cancer related.
BACKGROUND: Surgical resection for asymptomatic, localized, well-differentiated pancreatic neuroendocrine tumors (PNETs) is common yet controversial. Studies using overall survival as an endpoint have shown a benefit for resection; however, these results may be due to treatment selection bias. We assessed the impact of surgery on both overall (OS) and cancer-specific survival (CSS) for asymptomatic patients with stage I PNETs (AJCC 8th edition). METHODS: Using SEER data, we identified 709 patients from 2007 to 2015 with well- and moderately differentiated stage I PNETs. We performed Kaplan-Meier survival estimates and adjusted Cox regression for OS and CSS. RESULTS: Among 709 patients, 628 (88.6%) underwent surgery. There were 37 overall deaths and 11 cancer-specific deaths. All cancer-specific deaths occurred within 3 years of diagnosis. Five-year OS and CSS rates were 89% and 98%, respectively, for the population. Five-year OS rates were 56% in the non-surgical cohort versus 92% in the surgical cohort (log rank, p < 0.001). However, the 5-year CSS rates were similar; 94% in the non-surgical group and 98% in the surgical group (log rank, p = 0.207). On multivariable analysis, surgery predicted improved OS but not CSS. CONCLUSION: Although OS is superior in surgically treated stage I PNETs, CSS is not improved, implying treatment selection bias towards surgery being performed in healthier patients. These data suggest that overall survival is a problematic endpoint for the study of asymptomatic, stage I PNETs. Surgery should be individualized for this cohort of patients as the primary cause of death is non-cancer related.
Authors: Marianne Pavel; Eric Baudin; Anne Couvelard; Eric Krenning; Kjell Öberg; Thomas Steinmüller; Martin Anlauf; Bertram Wiedenmann; Ramon Salazar Journal: Neuroendocrinology Date: 2012-02-15 Impact factor: 4.914
Authors: Matthew H Kulke; Lowell B Anthony; David L Bushnell; Wouter W de Herder; Stanley J Goldsmith; David S Klimstra; Stephen J Marx; Janice L Pasieka; Rodney F Pommier; James C Yao; Robert T Jensen Journal: Pancreas Date: 2010-08 Impact factor: 3.327
Authors: Susan M Sharpe; Haejin In; David J Winchester; Mark S Talamonti; Marshall S Baker Journal: J Gastrointest Surg Date: 2014-08-26 Impact factor: 3.452
Authors: Andrea Frilling; Irvin M Modlin; Mark Kidd; Christopher Russell; Stefan Breitenstein; Riad Salem; Dik Kwekkeboom; Wan-yee Lau; Catherine Klersy; Valerie Vilgrain; Brian Davidson; Mark Siegler; Martyn Caplin; Enrico Solcia; Richard Schilsky Journal: Lancet Oncol Date: 2014-01 Impact factor: 41.316
Authors: Eran Sadot; Diane L Reidy-Lagunes; Laura H Tang; Richard Kinh Gian Do; Mithat Gonen; Michael I D'Angelica; Ronald P DeMatteo; T Peter Kingham; Bas Groot Koerkamp; Brian R Untch; Murray F Brennan; William R Jarnagin; Peter J Allen Journal: Ann Surg Oncol Date: 2015-11-23 Impact factor: 5.344
Authors: Louis C Lee; Clive S Grant; Diva R Salomao; Joel G Fletcher; Naoki Takahashi; Jeff L Fidler; Michael J Levy; Marianne Huebner Journal: Surgery Date: 2012-10-24 Impact factor: 3.982
Authors: Arvind Dasari; Chan Shen; Daniel Halperin; Bo Zhao; Shouhao Zhou; Ying Xu; Tina Shih; James C Yao Journal: JAMA Oncol Date: 2017-10-01 Impact factor: 31.777
Authors: Alex M Rosenberg; Patricia Friedmann; Jaydira Del Rivero; Steven K Libutti; Amanda M Laird Journal: Surgery Date: 2015-11-04 Impact factor: 3.982
Authors: Ashley L Titan; Jeffrey A Norton; Andrea T Fisher; Deshka S Foster; E John Harris; David J Worhunsky; Patrick J Worth; Monica M Dua; Brendan C Visser; George A Poultsides; Michael T Longaker; Robert T Jensen Journal: JAMA Netw Open Date: 2020-11-02